login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
VYNE THERAPEUTICS INC (VYNE) Stock News
USA
- NASDAQ:VYNE -
US92941V3087
-
Common Stock
0.3622
USD
+0 (+0.53%)
Last: 11/20/2025, 9:49:55 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
VYNE Latest News, Press Relases and Analysis
All
Press Releases
3 days ago - By: Benzinga
- Mentions:
AIM
NUVL
GLMD
VTGN
...
12 Health Care Stocks Moving In Monday's After-Market Session
14 days ago - By: VYNE Therapeutics Inc.
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
3 months ago - By: Zacks Investment Research
- Mentions:
CASI
VYNE Therapeutics Inc. (VYNE) Reports Q2 Loss, Lags Revenue Estimates
3 months ago - By: The Motley Fool
VYNE Reports Narrower Loss in Fiscal Q2
3 months ago - By: VYNE Therapeutics Inc.
VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update
3 months ago - By: Zacks Investment Research
- Mentions:
MGX
Metagenomi (MGX) Reports Q2 Loss, Tops Revenue Estimates
3 months ago - By: Zacks Investment Research
- Mentions:
AQST
Aquestive Therapeutics (AQST) Reports Q2 Loss, Lags Revenue Estimates
4 months ago - By: Zacks Investment Research
- Mentions:
CPRX
Catalyst Pharmaceutical (CPRX) Q2 Earnings and Revenues Surpass Estimates
4 months ago - By: Benzinga
- Mentions:
PBM
IDXX
EQ
REPL
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
4 months ago - By: Stocktwits
Vyne Hit With Downgrades After Repibresib Misses Endpoints In Vitiligo Trial; Traders Still Eye Rebound
4 months ago - By: Yahoo Finance
VYNE Therapeutics Inc. (VYNE) Gets Buy Reaffirmation on Pipeline Progress
5 months ago - By: VYNE Therapeutics Inc.
VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202
7 months ago - By: VYNE Therapeutics Inc.
VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update
7 months ago - By: VYNE Therapeutics Inc.
VYNE Therapeutics Provides Update on VYN202 Program
8 months ago - By: VYNE Therapeutics Inc.
VYNE Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
Please enable JavaScript to continue using this application.